Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00647790 · ClinicalTrials.gov registry record
Positron Emission Tomography (PET) Using Hormone Receptor Ligands in Breast Cancer
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 79
- Enrollment target
NCT00647790: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00647790 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 79 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00647790 has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 79 participants
- Enrollment target
Study Summary
The purpose of this study is to find a way to learn the hormone receptor status of a tumor before surgery is done. By testing for the hormone receptor proteins, doctors can find out if the breast cancer uses hormones to grow. This is important since the hormone receptor status of a tumor helps doctors decide if extra treatment like chemotherapy or pills are needed.
Interventions
- PROCEDURE PET scan with injection of 5-8 mCi of 18FES
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2006-11 |
| Est. Completion | 2013-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00647790
The ClinicalTrials.gov registry entry for NCT00647790 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PET scan with injection of 5-8 mCi of 18FES is the first listed.
NCT00647790 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00647790 about?
NCT00647790 is a clinical study titled "Positron Emission Tomography (PET) Using Hormone Receptor Ligands in Breast Cancer". The purpose of this study is to find a way to learn the hormone receptor status of a tumor before surgery is done. By testing for the hormone receptor proteins, doctors can find out if the breast cancer uses hormones to grow. This is important since the hormone receptor status of a tumor helps docto...
What is the current status of trial NCT00647790?
This trial is currently completed. The enrollment target is 79 participants. The study started on 2006-11. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00647790?
The interventions under investigation include: PET scan with injection of 5-8 mCi of 18FES (PROCEDURE).
Who is sponsoring clinical trial NCT00647790?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.